PE20191243A1 - Nuevos derivados de fenilo - Google Patents
Nuevos derivados de feniloInfo
- Publication number
- PE20191243A1 PE20191243A1 PE2019001339A PE2019001339A PE20191243A1 PE 20191243 A1 PE20191243 A1 PE 20191243A1 PE 2019001339 A PE2019001339 A PE 2019001339A PE 2019001339 A PE2019001339 A PE 2019001339A PE 20191243 A1 PE20191243 A1 PE 20191243A1
- Authority
- PE
- Peru
- Prior art keywords
- phenyl
- new derivatives
- methyl
- dinitrophenoxy
- intolerance
- Prior art date
Links
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical class [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 title 1
- LRJQZGXEGNOHBH-UHFFFAOYSA-N 5-[(2,4-dinitrophenoxy)methyl]-1-methyl-2-nitroimidazole Chemical compound [N+](=O)([O-])C1=C(OCC2=CN=C(N2C)[N+](=O)[O-])C=CC(=C1)[N+](=O)[O-] LRJQZGXEGNOHBH-UHFFFAOYSA-N 0.000 abstract 1
- 206010022489 Insulin Resistance Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 210000003470 mitochondria Anatomy 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/91—Nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/88—Nitrogen atoms, e.g. allantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Referido a derivados de fenilo, 5-[(2,4-dinitrofenoxi)metil]-1-metil-2-nitro-1H-imidazol o una sal farmaceuticamente aceptable de este. Estos compuestos regulan la actividad de la mitocondria, reduce la adiposidad, trata enfermedades que incluye la diabetes, o resistencia o intolerancia a la insulina.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762443244P | 2017-01-06 | 2017-01-06 | |
| US201762581355P | 2017-11-03 | 2017-11-03 | |
| US201762585326P | 2017-11-13 | 2017-11-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20191243A1 true PE20191243A1 (es) | 2019-09-16 |
Family
ID=61569353
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2019001339A PE20191243A1 (es) | 2017-01-06 | 2018-01-05 | Nuevos derivados de fenilo |
Country Status (26)
| Country | Link |
|---|---|
| US (4) | US10618875B2 (es) |
| EP (2) | EP4086242A1 (es) |
| JP (3) | JP7090088B2 (es) |
| KR (1) | KR102579648B1 (es) |
| CN (2) | CN110167918B (es) |
| AU (1) | AU2018205811B2 (es) |
| BR (1) | BR112019013371A2 (es) |
| CA (1) | CA3047138C (es) |
| CL (1) | CL2019001842A1 (es) |
| CO (1) | CO2019006865A2 (es) |
| DK (1) | DK3565806T3 (es) |
| ES (1) | ES2913431T3 (es) |
| GE (1) | GEP20217227B (es) |
| IL (1) | IL267868B (es) |
| LT (1) | LT3565806T (es) |
| MX (1) | MX2019007745A (es) |
| MY (1) | MY192778A (es) |
| PE (1) | PE20191243A1 (es) |
| PH (1) | PH12019501318A1 (es) |
| PL (1) | PL3565806T3 (es) |
| PT (1) | PT3565806T (es) |
| SA (1) | SA519402076B1 (es) |
| SI (1) | SI3565806T1 (es) |
| UA (1) | UA124026C2 (es) |
| WO (1) | WO2018129258A1 (es) |
| ZA (1) | ZA201903808B (es) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10738035B2 (en) | 2015-05-13 | 2020-08-11 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| MY198617A (en) | 2016-03-07 | 2023-09-11 | Enanta Pharm Inc | Hepatitis b antiviral agents |
| WO2018129258A1 (en) * | 2017-01-06 | 2018-07-12 | Gencia Corporation | Novel phenyl derivatives |
| IL272941B2 (en) | 2017-08-28 | 2023-03-01 | Enanta Pharm Inc | Antiviral agents for viral hepatitis b |
| WO2019143902A2 (en) | 2018-01-22 | 2019-07-25 | Enanta Pharmaceuticals, Inc. | Substituted heterocycles as antiviral agents |
| CN112955142A (zh) | 2018-09-21 | 2021-06-11 | 英安塔制药有限公司 | 官能化杂环化合物作为抗病毒剂 |
| SG11202105007TA (en) | 2018-11-21 | 2021-06-29 | Enanta Pharm Inc | Functionalized heterocycles as antiviral agents |
| WO2020247444A1 (en) | 2019-06-03 | 2020-12-10 | Enanta Pharmaceuticals, Inc, | Hepatitis b antiviral agents |
| WO2020247561A1 (en) | 2019-06-04 | 2020-12-10 | Enanta Pharmaceuticals, Inc, | Hepatitis b antiviral agents |
| WO2020247575A1 (en) | 2019-06-04 | 2020-12-10 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
| WO2021007488A1 (en) | 2019-07-11 | 2021-01-14 | Enanta Pharmaceuticals, Inc. | Substituted heterocycles as antiviral agents |
| WO2021055425A2 (en) | 2019-09-17 | 2021-03-25 | Enanta Pharmaceuticals, Inc. | Functionalized heterocycles as antiviral agents |
| WO2021188414A1 (en) | 2020-03-16 | 2021-09-23 | Enanta Pharmaceuticals, Inc. | Functionalized heterocyclic compounds as antiviral agents |
| BR112023024146A2 (pt) | 2021-05-20 | 2024-01-30 | Rivus Pharmaceuticals Inc | Métodos de tratamento de distúrbios relacionados às mitocôndrias |
| KR20240146053A (ko) | 2022-02-07 | 2024-10-07 | 리부스 파마슈티칼스, 인크. | 상승된 HbA1c를 갖는 대상체에서의 체중 감소 방법 |
| KR20240146052A (ko) | 2022-02-07 | 2024-10-07 | 리부스 파마슈티칼스, 인크. | 체중 감소 및 골격근 질량 보존 방법 |
| WO2024112659A1 (en) | 2022-11-21 | 2024-05-30 | Rivus Pharmaceuticals, Inc. | Crystalline forms of 5-[(2,4-dinitrophenoxy)methyl]-1-methyl-2-nitro-1h-imidazole |
| WO2024112663A1 (en) | 2022-11-21 | 2024-05-30 | Rivus Pharmaceuticals, Inc. | Deuterium enriched phenyl derivatives for treating mitochondriarelated disorders or conditions |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3828056A (en) * | 1972-09-11 | 1974-08-06 | Searle & Co | (2-(2-methyl-5-nitro-1-imidazolyl)ethyl)heteroaryloxy ethers |
| EG11928A (en) * | 1974-12-16 | 1979-03-31 | Hoechst Ag | Process for preparing of 1-alkyl-2-(phenoxy-methyl)-5-nitro-imidazoles |
| US5359078A (en) * | 1989-05-19 | 1994-10-25 | The United States Of America As Represented By The Department Of Health And Human Services | Signal transduction inhibitor compounds |
| EP1575575B1 (en) | 2002-11-08 | 2010-05-19 | High Point Pharmaceuticals, LLC | Safe chemical uncouplers for the treatment of obesity |
| DE602004022153D1 (de) | 2003-05-14 | 2009-09-03 | High Point Pharmaceuticals Llc | Verbindungen zur behandlung von obesitas |
| ATE403649T1 (de) * | 2003-05-27 | 2008-08-15 | Sod Conseils Rech Applic | Neue imidazolderivative, deren herstellung und deren verwendung als medikament |
| WO2005051894A1 (en) | 2003-11-25 | 2005-06-09 | Novo Nordisk A/S | Novel salicylic anilides |
| JP2007512262A (ja) | 2003-11-25 | 2007-05-17 | ノボ ノルディスク アクティーゼルスカブ | 肥満症の治療のための新規な化合物 |
| US20070010559A1 (en) | 2003-11-25 | 2007-01-11 | Novo Nordisk A/S | Indole derivatives for use as chemical uncoupler |
| SI1896040T1 (sl) | 2005-06-29 | 2012-12-31 | Threshold Pharmaceuticals, Inc. | Fosforamidatna alkilatorska predzdravila |
| CA2669867A1 (en) | 2006-11-15 | 2008-05-22 | High Point Pharmaceuticals, Llc | 2- ( 2 -hydroxyphenyl) -quinazolin-4-ones useful for treating obesity and diabetes |
| CA2669860A1 (en) | 2006-11-15 | 2008-05-22 | High Point Pharmaceuticals, Llc | New haloalkylsulfone substituted compounds useful for treating obesity and diabetes |
| WO2008059025A1 (en) | 2006-11-15 | 2008-05-22 | High Point Pharmaceuticals, Llc | Novel 2-(2-hydroxyphenyl) benzothiadiazines useful for treating obesity and diabetes |
| WO2008059026A1 (en) | 2006-11-15 | 2008-05-22 | High Point Pharmaceuticals, Llc | Novel 2-(2-hydroxyphenyl)benzimidazoles useful for treating obesity and diabetes |
| WO2010048330A1 (en) | 2008-10-21 | 2010-04-29 | Threshold Pharmaceuticals, Inc. | Treatment of cancer using hypoxia activated prodrugs |
| EP2179984A1 (en) * | 2008-10-27 | 2010-04-28 | Congenia S.r.l. | Acrylamido derivatives useful as inhibitors of the mitochondrial permeability transition |
| CN101560189B (zh) * | 2009-05-20 | 2011-02-16 | 南京大学 | 甲硝唑和取代水杨酸的复合物及其制法与用途 |
| US20130203843A1 (en) | 2010-06-24 | 2013-08-08 | Limited Liability Company Mitotech | Mild cationic mitochondrial uncouplers |
| US9492448B2 (en) | 2012-06-20 | 2016-11-15 | University Of Virginia Patent Foundation | Compositions and methods for regulating glucose homeostasis and insulin action |
| WO2015031598A2 (en) | 2013-08-30 | 2015-03-05 | Yale University | Therapeutic dnp derivatives and methods using same |
| JP6706204B2 (ja) | 2013-08-30 | 2020-06-03 | イエール ユニバーシティ | 新規２，４−ジニトロフェノール製剤およびその使用法 |
| PT3164125T (pt) | 2014-07-03 | 2023-12-12 | Silti Ag | Métodos e composições para tratar obesidade, prevenir ganho de peso, promover perda de peso, promover emagrecimento ou tratar ou prevenir o desenvolvimento de diabetes |
| US20160008298A1 (en) * | 2014-07-14 | 2016-01-14 | Oregon State University | Xanthohumol-based compounds and compositions thereof, and methods of making and using the same |
| WO2016118741A1 (en) | 2015-01-22 | 2016-07-28 | Mitochon Pharmaceuticals Llc | Induced expression of brain derived neurotrophic factor (bdnf) for treatment of neuromuscular, neurodegenerative, autoimmune, developmental and/or metabolic diseases |
| TWI794161B (zh) | 2016-03-07 | 2023-03-01 | 美商米托控製藥公司 | 神經肌肉性疾病、神經退化性疾病、自體免疫疾病、發育性疾病、創傷性腦損傷、震盪、乾眼症、聽力損失及／或代謝疾病之二硝基酚（ｄｎｐ）和ｄｎｐ前藥治療 |
| WO2018129258A1 (en) * | 2017-01-06 | 2018-07-12 | Gencia Corporation | Novel phenyl derivatives |
| JP2020520949A (ja) | 2017-05-22 | 2020-07-16 | ユニバーシティ オブ ヴァージニア パテント ファウンデーションＵｎｉｖｅｒｓｉｔｙ Ｏｆ Ｖｅｒｇｉｎｉａ Ｐａｔｅｎｔ Ｆｏｕｎｄａｔｉｏｎ | 組成物、並びにミトコンドリア脱共役剤を調製及び使用する方法 |
-
2018
- 2018-01-05 WO PCT/US2018/012491 patent/WO2018129258A1/en active Application Filing
- 2018-01-05 LT LTEPPCT/US2018/012491T patent/LT3565806T/lt unknown
- 2018-01-05 DK DK18709129.3T patent/DK3565806T3/da active
- 2018-01-05 BR BR112019013371A patent/BR112019013371A2/pt active Search and Examination
- 2018-01-05 PE PE2019001339A patent/PE20191243A1/es unknown
- 2018-01-05 CN CN201880005988.7A patent/CN110167918B/zh active Active
- 2018-01-05 PT PT187091293T patent/PT3565806T/pt unknown
- 2018-01-05 KR KR1020197018983A patent/KR102579648B1/ko active IP Right Grant
- 2018-01-05 ES ES18709129T patent/ES2913431T3/es active Active
- 2018-01-05 GE GEAP201815132A patent/GEP20217227B/en unknown
- 2018-01-05 EP EP22157494.0A patent/EP4086242A1/en active Pending
- 2018-01-05 PL PL18709129T patent/PL3565806T3/pl unknown
- 2018-01-05 US US16/475,390 patent/US10618875B2/en active Active
- 2018-01-05 UA UAA201906673A patent/UA124026C2/uk unknown
- 2018-01-05 CA CA3047138A patent/CA3047138C/en active Active
- 2018-01-05 JP JP2019537086A patent/JP7090088B2/ja active Active
- 2018-01-05 CN CN202310980210.0A patent/CN117024351A/zh active Pending
- 2018-01-05 EP EP18709129.3A patent/EP3565806B1/en active Active
- 2018-01-05 AU AU2018205811A patent/AU2018205811B2/en active Active
- 2018-01-05 MY MYPI2019003195A patent/MY192778A/en unknown
- 2018-01-05 MX MX2019007745A patent/MX2019007745A/es unknown
- 2018-01-05 SI SI201830676T patent/SI3565806T1/sl unknown
-
2019
- 2019-06-11 PH PH12019501318A patent/PH12019501318A1/en unknown
- 2019-06-12 ZA ZA2019/03808A patent/ZA201903808B/en unknown
- 2019-06-27 CO CONC2019/0006865A patent/CO2019006865A2/es unknown
- 2019-07-03 CL CL2019001842A patent/CL2019001842A1/es unknown
- 2019-07-04 IL IL267868A patent/IL267868B/en unknown
- 2019-07-07 SA SA519402076A patent/SA519402076B1/ar unknown
-
2020
- 2020-09-02 US US17/010,547 patent/US20200399225A1/en not_active Abandoned
-
2021
- 2021-04-15 US US17/231,168 patent/US20210238144A1/en not_active Abandoned
- 2021-10-28 US US17/513,235 patent/US20220048865A1/en not_active Abandoned
-
2022
- 2022-06-13 JP JP2022095049A patent/JP2022120118A/ja active Pending
-
2024
- 2024-06-12 JP JP2024095420A patent/JP2024116328A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20191243A1 (es) | Nuevos derivados de fenilo | |
| CL2019003126A1 (es) | Métodos de tratamiento mediante el uso de un compuesto inhibidor de jak. | |
| BR112015029258A2 (pt) | compostos hetericíclicos como agentes de controle de pestes | |
| CL2022001529A1 (es) | Nuevos derivados de metilquinazolinona | |
| UA110653C2 (uk) | Фунгіцидна композиція і спосіб боротьби з хворобами рослин | |
| AR095034A1 (es) | El uso de los agonistas del receptor 2 del péptido formilo para el tratamiento de las enfermedades inflamatorias oculares | |
| EA201500953A1 (ru) | 3-ацетиламино-1-(фенилгетероариламинокарбонил или фенилгетероарилкарбониламино)бензольные производные для лечения гиперпролиферативных нарушений | |
| BR112017011316A2 (pt) | derivados heterocíclicos e uso destes | |
| BR112015030399A2 (pt) | derivados heterocíclicos e uso dos mesmos | |
| CY1119118T1 (el) | Θεραπευτικος παραγων για τις διαταραχες της διαθεσης | |
| CL2021000515A1 (es) | Amidas heterocíclicas de 5 a 7 miembros como inhibidores de jak | |
| MX2020003732A (es) | Derivado de anillo fusionado como inhibidor del receptor a2a. | |
| BR112016002383A2 (pt) | composto, composição herbicida, método para controlar plantas indesejáveis, e, uso de um composto | |
| CL2016003023A1 (es) | “compuestos derivados de (bencil-piperazin-1-il)(tetrahidrofuran-carbonil o tetrahidropiran-carbonil) sustituido, moduladores rorg; composición farmacéutica que los comprende; y su uso en el tratamiento de la esclerosis múltiple y espondilitis anquilosante”. pct | |
| MY197561A (en) | Composition for increasing expression of pgc-1? | |
| BR112018008006A2 (pt) | composto de piranodipiridina | |
| CY1119483T1 (el) | Θεραπευτικος παραγων για τις αγχωδεις διαταραχες | |
| AR099767A1 (es) | Derivados del ácido acético azaindol y su uso como moduladores del receptor de prostaglandina d2 | |
| DOP2018000134A (es) | Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cáncer | |
| EA201990550A1 (ru) | Офтальмологический препарат, включающий азоловое соединение | |
| BR112015010823A2 (pt) | composto de 2-piridona | |
| MX2016011310A (es) | Agente para el control de endoparasitos. | |
| EA201991180A1 (ru) | Новые фенильные производные | |
| AR115865A2 (es) | Compuestos terapéuticos | |
| MD4317B1 (en) | Use of 3-(2,2,2-trimethylhydrazinium)propionate dihydrate for treating patients with advanced liver cirrhosis associated with heart failure |